Newly found mechanism can supercharge the immune system against cancers
2025-08-04T11:35:00+10:00
New research could pave the way for more personalised, effective immunotherapy treatments against a range of cancers.
Photo: Adobe Stock
Researchers have discovered new pathways that may explain differences in the way people with cancer respond to immunotherapy.
New research has uncovered a novel mechanism that may help explain why some people with cancer respond remarkably well to immunotherapy while others don鈥檛.聽聽
Researchers from the and 草莓视频 Sydney have uncovered that less active versions of a gene called NOD2, in combination with radiotherapy or immunotherapy, may help supercharge the immune system鈥檚 ability to attack cancer.聽
The findings, published in the journal ,聽could pave the way for more personalised and effective immunotherapy treatments against a range of cancers.聽
Immunotherapy fights cancer, but not everyone responds equally聽
Immunotherapy has emerged as one of the most significant advances in cancer treatment in recent decades. It works by recruiting the body鈥檚 immune system to recognise and eliminate cancer cells. But not everyone responds equally, with some experiencing strong immune activation, while others experience no effect.聽
One widely used cancer immunotherapy is called anti-PD1, part of a family of treatments called checkpoint inhibitors. Normally, cancer evades elimination by the immune system by putting a brake on the action of immune cells.聽Checkpoint inhibitors release this brake, allowing the immune system to see and destroy cancer cells.聽
Anti-PD1 therapy is now commonly used for treating many cancers, including lung, skin, blood and gastrointestinal cancers.聽
鈥淎nti-PD1 therapy has become part of standard treatment for many cancers. But only a minority of people experience a really significant benefit, and we don鈥檛 completely understand why,鈥 says 草莓视频 Conjoint Associate Professor a clinician researcher at Garvan and co-lead of the study.
Media enquiries
For enquiries about this story and interview requests, please contact聽Kate Burke, News & Content Coordinator, 草莓视频 Medicine & Health.
罢别濒:听+61 2 9348 2538
贰尘补颈濒:听kate.burke@unsw.edu.au
A new mechanism to boost immunotherapy
To understand why some people respond well to anti-PD1 and others don鈥檛, researchers studied a group of people who responded exceptionally well to this therapy.
From a group of 742 Australians with the most common form of advanced lung cancer who underwent treatment with anti-PD1, the team identified 40 whose immune system responded very well, as seen by longer survival accompanied by autoimmune reactions. When the researchers analysed their inherited genes, they found they were more than twice as likely as the general population to have less active versions of a gene called NOD2, in combination with an autoimmune type reaction caused by the immunotherapy.
鈥淭his suggests that blocking two different mechanisms, one governed by PD1 and the other by NOD2, combines to supercharge the immune system against cancer cells. This was a surprising finding and points to the marvel and complexity of the immune system,鈥 says study co-lead Professor聽Chris Goodnow, Laboratory Head at Garvan and Professor in the聽听补苍诲听School of Biomedical Sciences聽at 草莓视频.
Encouragingly, the immune-boosting effect of NOD2 was not limited to lung cancer. The team showed that in 160 people with a range of cancers who had undergone聽anti-PD1聽treatment, those who had less active versions of NOD2 showed a better response to the therapy. Furthermore, the role of the NOD2 pathway in immunotherapy response was confirmed in preclinical models of colorectal cancer.
鈥淭hese findings are important because they help us understand the role of the patient as well as the cancer in responding to immune therapy,鈥 says A/Prof. Barnet. 鈥淟ess active versions of the immune regulator gene NOD2 are often found in people with Crohn鈥檚 disease, an autoinflammatory condition of the gut. This was the first time that the gene has been identified as playing a role in anti-cancer response to immunotherapy.鈥
Prof. Goodnow adds: 鈥淲e believe that for those people undergoing anti-PD1 therapy and experiencing an autoimmune-like response to the treatment, having less active NOD2 gives the immune system an additional nudge to attack and eliminate cancer cells. This is exciting as it suggests that the action of immunotherapies could be boosted through several complementary pathways.鈥
The importance of understanding exceptional responses to therapy
The team is now investigating 鈥榚xceptional responders鈥 鈥 both people who respond very well or very poorly to treatment 鈥 across a variety of cancers and therapies. This is an established research led by the Garvan.
Prof. Goodnow states: 鈥淏uilding on the success of the exceptional responder approach, A/Prof. Barnet and the team is expanding its focus to study different cancers and treatments including chemotherapy. Our aim is to better predict therapeutic responses, to deliver a more personalised approach to cancer treatment, and in turn achieve better outcomes for people with cancer.鈥
This research was supported through an NHMRC Investigator Grant, the Bill and Patricia Ritchie Foundation Chair in Immunogenomics and the Exceptional Responders Program from Bioplatforms Australia and the Kinghorn Foundation.
